« Previous
Next »
Titles
- DSCSA standards for the interoperable exchange of information for tracing of certain human, finished, prescription drugs: guidance for industry1
- Data science: NIH needs to implement key workforce planning activities : report to congressional committees1
- Defense health agency: oversight needed to better ensure that children are screened, tested, and treated for lead exposure : report to congressional committees1
- Defense health care: Actions needed to improve billing and collection of debt for civilian emergency care : report to congressional committees1
- Defense health care: Additional assessments needed to determine effects of active duty medical personnel reductions : report to congressional committees1
- Defense health care: DOD assessment needed to ensure TRICARE behavioral health coverage goals are being met : report to congressional committees1
- Defense health care: DOD expects new IT system capabilities to improve other health insurance processing : report to congressional committees1
- Defense health care: Improved monitoring could help ensure completion of mandated reforms : report to congressional committees1
- Defense health care: Prevalence of and efforts to screen and treat mental health conditions in prenatal and postpartum TRICARE beneficiaries : report to congressional committees1
- Definitions of suspect product and illegitimate product for verification obligations under the Drug Supply Chain Security Act: guidance for industry1
- Development and licensure of vaccines to prevent COVID-19: guidance for industry1
- Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use authorization: guidance for industry1
- Digital health technologies for remote data acquisition in clinical investigations: guidance for industry, investigators, and other stakeholders1
- Direct-to-consumer prescription drug advertisements: presentation of the major statement in a clear, conspicuous, and neutral manner in advertisements in television and radio format final rule : questions and answers : guidance for industry1
- Drug manufacturing: FDA should fully assess its efforts to encourage innovation : report to congressional committees1
- Drug safety: FDA should take additional steps to improve its foreign inspection program : report to congressional requesters1
- Drug-drug interaction assessment for therapeutic proteins: guidance for industry1
- During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections1